Short Interest in Nanovibronix, Inc. (NASDAQ:FEED) Increases By 1,387.8%

Nanovibronix, Inc. (NASDAQ:FEED) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 163,391 shares, a growth of 1,387.8% from the April 30th total of 10,982 shares. Currently, 2.7% of the shares of the company are short sold. Based on an average daily trading volume, of 982,721 shares, the short-interest ratio is presently 0.2 days.

Nanovibronix Stock Down 0.7%

Shares of NASDAQ FEED opened at $0.92 on Thursday. Nanovibronix has a 52 week low of $0.84 and a 52 week high of $17.40. The company has a market capitalization of $5.60 million, a PE ratio of -0.10 and a beta of 1.59. The stock has a fifty day moving average of $1.49.

Nanovibronix (NASDAQ:FEED) last issued its quarterly earnings results on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.The company had revenue of $0.65 million during the quarter.

Analyst Ratings Changes

FEED has been the topic of several recent research reports. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Nanovibronix currently has an average rating of “Sell”.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.